CME REVIEW ARTICLE
Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic

https://doi.org/10.1016/S1081-1206(10)61566-9Get rights and content

Background

All antihistamines are capable of crossing the blood-brain barrier and thus may cause sedation. Most antihistamine users are ambulatory patients and therefore presumably drive a car.

Objective

To summarize the effects of antihistamine drugs on driving ability.

Data Sources and Study Selection

A literature search (MEDLINE and cross-references) was performed using the keywords driving and antihistamine. Sixteen studies using the on-the-road driving test during normal traffic were included in the review. Studies were double-blind and placebo-controlled and included a positive control.

Results

First-generation antihistamines (diphenhydramine, triprolidine, terfenadine, dexchlorpheniramine, clemastine) significantly impair driving performance after both one-time and repeated (daily) administration. Second-generation antihistamines (cetirizine, loratadine, ebastine, mizolastine, acrivastine, emedastine, mequitazine) may also impair driving performance, but the magnitude and extent of impairment depend on the administered dose, sex, and time between testing and treatment administration. Tolerance develops after 4 to 5 days of administration, but impairment is not absent. Third-generation antihistamines (fexofenadine and levocetirizine) have been shown to produce no driving impairment after both one-time and repeated administration.

Conclusions

First- and second-generation antihistamines may significantly impair driving performance. In the context of driving safety but also taking into account the cardiotoxic properties of some of the second-generation antihistamines, we advise treating patients with third-generation antihistamines such as fexofenadine and levocetirizine.

REFERENCES (42)

  • JW Louwerens et al.

    The relationship between drivers' blood alcohol concentration (BAC) and actual driving performance during high speed travel.

  • WJ Riedel et al.

    Sedation and performance impairment with antihistamines.

  • WJ Riedel et al.

    Higher Doses of Terfenadine and Loratadine. Acute and Subchronic Effects on Psychomotor and Actual Driving Performance, Institute for Drugs, Safety & Behavior

    (1990)
  • HW Robbe et al.

    Effects of Acrivastine, Acrivastine Plus Pseudoephedrine and Triprolidine on Highway Driving, Institute for Drugs, Safety & Behavior

    (1990)
  • ER Volkerts et al.

    Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness

    Hum Psychopharmacol.

    (1992)
  • KA Brookhuis et al.

    Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 0 and 30 mg dose, and triprolidine 10 mg on car driving performance

    Br J Clin Pharmacol.

    (1993)
  • JG Ramaekers et al.

    Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing

    Eur J Clin Pharmacol.

    (1994)
  • JC Verster et al.

    Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial

    Psychopharmacology (Berl).

    (2003)
  • EF Vuurman et al.

    Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers

    Eur J Clin Pharmacol.

    (1994)
  • EA Schoenmakers et al.

    Het Effect van Terfenadine op de Rijvaardigheid van Geselecteerde Patienten

    (1987)
  • EL Theunissen et al.

    Acute and subchronic effects of mequitazine on actual driving, memory, and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo

    J Psychopharmacol.

    (2003)
  • Cited by (0)

    Supported by an unrestricted educational grant from AstraZeneca LP

    View full text